RecruitingPhase 2NCT06451211
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Studying Gastric linitis plastica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Principal Investigator
- Haibo Qiu, MD, Ph.DSun Yat-sen University
- Intervention
- Tislelizumab(drug)
- Enrollment
- 53 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06451211 on ClinicalTrials.gov